Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Barton

Showing results (101-110 of 111) with videos related to

Pageof 12
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2025
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression StudyNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 31, 2026
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study - RETRACTIONNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
Journal of Affective Disorders|May 29, 2025
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS studyMary Lou Chatterton, Johana Kevin Perez, Thao Thai, et al.
Community Genetics|June 19, 2007
Report of an international survey of molecular genetic testing laboratoriesMargaret M McGovern, Rob Elles, Isabella Beretta, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
JAMA Neurology|November 4, 2024
Deferiprone in Alzheimer Disease: A Randomized Clinical TrialScott Ayton, David Barton, Bruce Brew, et al.
European Journal of Human Genetics : EJHG|February 25, 2010
EMQN Best Practice Guidelines for molecular genetic testing of SCAsJorge Sequeiros, Joanne Martindale, Sara Seneca, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 14, 2024
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUMColleen Loo, Nick Glozier, David Barton, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 18, 2023
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trialColleen Loo, Nick Glozier, David Barton, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 12

Showing results (101-110 of 111) with videos related to

Sort By:
Pageof 12
The British Journal of Psychiatry : the Journal of Mental Science|January 7, 2025
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression StudyNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|March 31, 2026
Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study - RETRACTIONNatalie T Mills, Stevan Nikolin, Nick Glozier, et al.
Journal of Affective Disorders|May 29, 2025
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS studyMary Lou Chatterton, Johana Kevin Perez, Thao Thai, et al.
Community Genetics|June 19, 2007
Report of an international survey of molecular genetic testing laboratoriesMargaret M McGovern, Rob Elles, Isabella Beretta, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 6, 2026
Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS studyNick Glozier, Richard Morris, Elizabeth Stratton, et al.
JAMA Neurology|November 4, 2024
Deferiprone in Alzheimer Disease: A Randomized Clinical TrialScott Ayton, David Barton, Bruce Brew, et al.
European Journal of Human Genetics : EJHG|February 25, 2010
EMQN Best Practice Guidelines for molecular genetic testing of SCAsJorge Sequeiros, Joanne Martindale, Sara Seneca, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 14, 2024
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUMColleen Loo, Nick Glozier, David Barton, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 18, 2023
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trialColleen Loo, Nick Glozier, David Barton, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 12